Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin

Eur Heart J. 2016 Jun 7;37(22):1720-2. doi: 10.1093/eurheartj/ehw024. Epub 2016 Feb 22.
No abstract available

Publication types

  • Review

MeSH terms

  • Anti-Inflammatory Agents / therapeutic use
  • Anticholesteremic Agents / therapeutic use
  • Biomarkers / metabolism
  • Cholesterol, LDL / metabolism
  • Clinical Trials as Topic
  • Coronary Artery Disease / prevention & control*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hypercholesterolemia / prevention & control
  • Recurrence
  • Risk Factors
  • Vasculitis / prevention & control*

Substances

  • Anti-Inflammatory Agents
  • Anticholesteremic Agents
  • Biomarkers
  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors